Travere Therapeutics (NASDAQ:TVTX) Shares Gap Up After Analyst Upgrade

Travere Therapeutics, Inc. (NASDAQ:TVTX) gapped up before the market opened on Friday after Wedbush raised their price target on the stock from $13.00 to $16.00. The stock had previously closed at $9.24, but opened at $10.02. Wedbush currently has an outperform rating on the stock. Travere Therapeutics shares last traded at $9.10, with a volume of 62,806 shares.

Several other equities research analysts also recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $19.00 price target on shares of Travere Therapeutics in a research report on Tuesday, May 7th. Canaccord Genuity Group lifted their price target on Travere Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, May 7th. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $14.91.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. ProShare Advisors LLC raised its stake in shares of Travere Therapeutics by 9.2% in the 1st quarter. ProShare Advisors LLC now owns 18,421 shares of the company’s stock valued at $142,000 after acquiring an additional 1,557 shares in the last quarter. Arizona State Retirement System grew its position in Travere Therapeutics by 9.7% in the 4th quarter. Arizona State Retirement System now owns 20,969 shares of the company’s stock worth $189,000 after purchasing an additional 1,851 shares during the last quarter. Signaturefd LLC raised its position in shares of Travere Therapeutics by 1,656.4% during the fourth quarter. Signaturefd LLC now owns 3,021 shares of the company’s stock valued at $27,000 after buying an additional 2,849 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Travere Therapeutics by 10.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 31,009 shares of the company’s stock valued at $240,000 after buying an additional 2,948 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Travere Therapeutics by 7.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 46,424 shares of the company’s stock worth $417,000 after buying an additional 3,083 shares in the last quarter.

Travere Therapeutics Stock Down 1.5 %

The firm has a 50 day moving average of $8.30 and a 200-day moving average of $7.77. The company has a debt-to-equity ratio of 5.10, a current ratio of 2.78 and a quick ratio of 2.75. The stock has a market capitalization of $692.78 million, a P/E ratio of -4.40 and a beta of 0.77.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings data on Monday, May 6th. The company reported ($1.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.78). The firm had revenue of $41.40 million for the quarter, compared to the consensus estimate of $43.46 million. Travere Therapeutics had a negative net margin of 87.94% and a negative return on equity of 238.06%. The business’s revenue for the quarter was up 34.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.27) earnings per share. On average, equities research analysts expect that Travere Therapeutics, Inc. will post -3.92 earnings per share for the current fiscal year.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.